bioRxivCancer Biology
Zebrafish Drug Screening Identifies Erlotinib as an Inhibitor of Wnt/β-Catenin Signaling and Self-Renewal in T-cell Acute Lymphoblastic Leukemia
M. A. Al-Hamaly, A. H. Cox, M. G. Haney, W. Zhang, E. C. Arvin, S. Sampathi, M. Wimsett, J. S. Blackburn
Abstract
The Wnt/{beta}-catenin pathways significance in cancer initiation, progression, and stem cell biology underscores its therapeutic potential, yet clinical application of Wnt inhibitors remains limited due to challenges posed by off-target effects and complex crosstalk with other pathways. In this study, we leveraged the zebrafish model to perform a robust and rapid drug screening of 773 FDA-approved compounds to identify Wnt/{beta}-catenin inhibitors with minimal toxicity. Utilizing zebrafish expressing a Wnt reporter, we identified several drugs that suppressed Wnt signaling without compromising zebrafish development. The efficacy of the top hit, Erlotinib, extended to human cells, where it blocked Wnt/{beta}-catenin signaling downstream of the destruction complex. Notably, Erlotinib treatment reduced self-renewal in human T-cell Acute Lymphoblastic Leukemia cells, which are known to rely on active {beta}-catenin signaling for maintenance of leukemia-initiating cells. Erlotinib also reduced leukemia-initiating cell frequency and delayed disease formation in zebrafish models. This study underscores zebrafishs translational potential in drug discovery and repurposing, and highlights a new use for Erlotinib as a Wnt inhibitor for cancers driven by aberrant Wnt/{beta}-catenin signaling. HighlightsO_LIZebrafish-based drug screening offers an inexpensive and robust platform for identifying compounds with high efficacy and low toxicity in vivo. C_LIO_LIErlotinib, an Epidermal Growth Factor Receptor (EGFR) inhibitor, emerged as a potent and promising Wnt inhibitor with effects in both zebrafish and human cell-based Wnt reporter assays. C_LIO_LIThe identification of Erlotinib as a Wnt inhibitor underscores the value of repurposed drugs in developing targeted therapies to disrupt cancer stemness and improve clinical outcomes C_LI Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=42 SRC="FIGDIR/small/555200v1_ufig1.gif" ALT="Figure 1"> View larger version (14K): org.highwire.dtl.DTLVardef@150e0a0org.highwire.dtl.DTLVardef@cb3455org.highwire.dtl.DTLVardef@d8d8a8org.highwire.dtl.DTLVardef@780535_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: zebrafish
- organism: human
- assay: proteomics
- research focus: drug response / drug discovery
- research focus: cell type annotation
- research focus: differential expression
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Preclinical efficacy and safety of Tegavivint in Wnt-activated hepatocellular carcinoma
Toshiyasu Suzuki, Ciara Curran, … Thomas Graham Bird·bioRxiv·Jul 16, 2026
- Discovery of small molecule inhibitors of the PTK7/β-catenin interaction targeting the Wnt signaling pathway in colorectal cancer
L. Ganier, S. Betzi, … J.-P. Borg·bioRxiv·Oct 15, 2021
- β-catenin activity induces an RNA biosynthesis program promoting therapy resistance in T Acute Lymphoblastic Leukemia
V. Garcia-Hernandez, D. Arambilet, … A. Bigas·bioRxiv·Jul 7, 2022
- Transcriptional Rewiring of BET Inhibitor Treated Ewing Sarcoma Cells Augments their Dependency on Focal Adhesion Kinase
Shireen S. Ganapathi, Emma D. Wrenn, … Elizabeth R. Lawlor·bioRxiv·Sep 2, 2025
- Phosphorylation-driven Targeted Protein Degradation of Oncogenic β-catenin
Lucie Wolf, Juline Poirson, … Stéphane Angers·bioRxiv·Mar 18, 2026
- Wnt/β-catenin inhibition disrupts drug-tolerance in isogenic carboplatin-resistant models of Triple-Negative Breast Cancer.
W. A. Abreu de Oliveira, S. Moens, … F. Lluis·bioRxiv·May 21, 2021